Screen Reader Mode Icon
Please complete the following post-activity survey and evaluation questions so we can review our goals, objectives, and topics for future events. If you complete the Evaluation Questions and provide contact information, you will receive a Certificate of Participation.

Question Title

* 1. Name

Question Title

* 2. Title (MD/DO, NP/PA, PharmD, Other):

Question Title

* 3. Speciality (ex. Urologist, medical oncologist, pathologist, genetic counselor, etc):

Question Title

* 4. Organization

Question Title

* 5. City & Country

Question Title

* 6. Email address

Question Title

* 7. What drug class do poly(ADP)-ribose polymerase (PARP) inhibitors belong to?

Question Title

* 8. What is the mechanism of action of poly(ADP)-ribose polymerase (PARP) inhibitors?

Question Title

* 9. Which one of the following drugs is approved for metastatic castrate-resistant prostate cancer?

Question Title

* 10. Which one of the following trials supports the use of rucaparib in metastatic prostate cancer?

Question Title

* 11. Which of the following combination regimens has not been tried in prostate cancer?

Question Title

* 12. Prostate Cancer Symposium: On a scale of 0 (worst possible rating) to 10 (best possible rating), please rate your overall satisfaction

Question Title

* 13. Prostate Cancer Symposium: I feel this Symposium addressed the learning objectives:

Question Title

* 14. Prostate Cancer Symposium: The speaker(s) was/were knowledgeable on the topic:

Question Title

* 15. Prostate Cancer Symposium: The content was presented in a balanced manner:

Question Title

* 16. Prostate Cancer Symposium: Please rate your level of knowledge in Learning Objective #1: “Explaining mechanisms of action and risks associated with PARPi alone, as well as in combination with AR inhibitors currently used in practice” following the event:

Question Title

* 17. Prostate Cancer Symposium: Please rate your level of knowledge in Learning Objective #2: “Identifying and listing gene mutations that are predictive biomarkers to identify PARPi +AR inhibitor-responding mCRPC patients” following the event:

Question Title

* 18. Which one of the following anti-PD-(L)1 drugs has not been approved by the FDA for urothelial carcinoma?

Question Title

* 19. Maintenance therapy for la/mUC patients has now been recommended as a standard of care by both the National Comprehensive Cancer Network and the European Society for Medical Oncology?

Question Title

* 20. The JAVELIN clinical trial demonstrated which one of the following:

Question Title

* 21. A 65-year-old female patient with locally advanced UC who has received 4 cycles of 1L platinum-containing chemotherapy shows an increased overall survival benefit following chemotherapy. Following a standard Response Evaluation Criteria in Solid Tumours, the patient’s tumour diameter has only increased by 5%. Current data from prospective clinical trials and real-world studies suggest that this patient:

Question Title

* 22. A 75-year-old male who is cisplatin-ineligible received gem-carbo for metastatic disease and had disease progression- received pembrolizumab and progressed within 3 months. He has significant neuropathy. The tumour has an FGFR3 mutation.
What will you use next?

Question Title

* 23. A 59-year-old man is diagnosed with chronic-phase chronic myeloid leukemia and started on imatinib as first-line treatment. He meets his 3-month milestone of PCR measuring BCR-ABL1 <10% IS, and this is measured at 0.23% IS by 9 months. However, at 1 year his PCR is back up to 7% IS. A kinase domain mutation analysis is checked and reveals the presence of a T315I mutation. Which TKI would be the most appropriate second-line treatment option for this patient?

Question Title

* 24. In the ASCEMBL trial, asciminib was compared to bosutinib as a third-line treatment. What is the only adverse event which was more prevalent in the Asciminib arm compared to bosutinib treated patients?

Question Title

* 25. Where does asciminib bind to the BCR-ABL1 protein?

Question Title

* 26. A 54-year-old man was diagnosed with CML 12 months ago. The patient was started on imatinib 400 mg daily. The patient has mild fatigue and diarrhea from imatinib. PCR at 3 months demonstrated a BCR-ABL1 level 7.1% IS. At 12 months, the BCR-ABL1 increased to 12%. What is your next step?

Question Title

* 27. A 60-year-old woman was diagnosed with CML 12 months ago. The patient was started on imatinib 400 mg daily. Has mild fatigue and diarrhea from imatinib. PCR at 3 months demonstrated a BCR-ABL1 level 7.1% IS. At 12 months, the BCR-ABL1 increased to 12%. The patient is adherent to her medications. A BCR-ABL1 mutation analysis demonstrated the presence of a T315I mutation. What is your next step?

Question Title

* 28. CML Therapy Symposium: On a scale of 0 (worst possible rating) to 10 (best possible rating), please rate your overall satisfaction

Question Title

* 29. CML Therapy Symposium: I feel this Symposium addressed the learning objectives:

Question Title

* 30. CML Therapy Symposium: The speaker(s) was/were knowledgeable on the topic:

Question Title

* 31. CML Therapy Symposium: The content was presented in a balanced manner:

Question Title

* 32. CML Therapy Symposium: Please rate your level of knowledge in Learning Objectives following the event:

Question Title

* 33. Urothelial Carcinoma Symposium: On a scale of 0 (worst possible rating) to 10 (best possible rating), please rate your overall satisfaction

Question Title

* 34. Urothelial Carcinoma Symposium: I feel this Symposium addressed the learning objectives:

Question Title

* 35. Urothelial Carcinoma Symposium: The speaker(s) was/were knowledgeable on the topic:

Question Title

* 36. Urothelial Carcinoma Symposium: The content was presented in a balanced manner:

Question Title

* 37. Urothelial Carcinoma Symposium: Please rate your level of knowledge in Learning Objective #1: “Understand and explain relevant and current clinical trials and updates regarding immunotherapy as maintenance therapy in la/mUC patients” following the event:

Question Title

* 38. Urothelial Carcinoma Symposium: Please rate your level of knowledge in Learning Objective #2: “Understand which la/mUC patients should be followed up with immunotherapy maintenance treatment” following the event:

Question Title

* 39. Did you find any conflicts of interest or any commercial interest in any of the talks/sessions/symposia?

Question Title

* 40. Any comments regarding any potential knowledge gaps/topics/areas to focus on for next year's event

Question Title

* 41. Please feel free to add any other additional comments you may have. 

0 of 41 answered
 

T